Marcus Werner Koch (Eva Mm Strijbis, Marcus Koch, Marcus W Koch, Marcus W Koch, M W Koch)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 24

Top Venues

Multiple sclerosis (Houndmills, Basingstoke, England)

European journal of neurology

Journal of neurology

Neurology

University of Calgary

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Calgary Oct 01 2013

Canada

Assistant Professor :: Department of Community Health Sciences

Alberta Health Services Apr 01 2011

Canada

Neurologist

University of Calgary Apr 01 2011

Canada

Assistant Professor :: Department of Clinical Neurosciences

Universitair Medisch Centrum Groningen Apr 01 2004 - Oct 01 2010

Netherlands

Resident Physician :: Department of Neurology

Publications

Marcus Werner Koch, Carlos Camara-Lemarroy, Eva M M Strijbis, Jop Mostert, Victoria M Leavitt, Pavle Repovic, James D Bowen, Jacynthe Comtois, Bernard Uitdehaag, Gary R Cutter
Selecting informative patients for phase 2 progressive trials in MS: Design considerations for phase 2 clinical trials in progressive MS. Multiple sclerosis (Houndmills, Basingstoke, England) (2024)
Eline Me Coerver, Sezgi Kaçar, Olga Ciccarelli, Maria Pia Sormani, Frederik Barkhof, Douglas Lorne Arnold, Menno Michiel Schoonheim, Zoé LE Van Kempen, Jop Mostert, Zoé Léonie Elise van Kempen, Joep Killestein, Arman Eshaghi, Bernard Mj Uitdehaag, Marcus Werner Koch
Aging is associated with reduced inflammatory disease activity independent of disease duration in relapsing multiple sclerosis trial populations. Multiple sclerosis (Houndmills, Basingstoke, England) (2024)
Kathryn C Fitzgerald, Maria Pia Sormani, Sean Apap Mangion, Francesca Bovis, Winson Y Cheung, Gary R Cutter, Peter Feys, Michael D Hill, Marcus Werner Koch, Morgan C McCreary, Ellen M Mowry, Jay Jh Park, Fredrik Piehl, Salter Amber, Jeremy Chataway
Improving the efficiency of clinical trials in multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England) 29 (9) (2023)
Eva M M Strijbis, Eline Me Coerver, Jop Mostert, Zoé Léonie Elise van Kempen, Joep Killestein, Jacynthe Comtois, Pavle Repovic, James D Bowen, Gary Cutter, Marcus Werner Koch
Association of age and inflammatory disease activity in the pivotal natalizumab clinical trials in relapsing-remitting multiple sclerosis. Journal of neurology, neurosurgery, and psychiatry (2023)
Eline Me Coerver, S Janssens, A Ahmed, M H J Wessels, Z L E Van Kempen, M M S Jasperse, F Barkhof, Marcus Werner Koch, J Mostert, B M J Uitdehaag, Joep Killestein, Eva M M Strijbis
The association between age and inflammatory disease activity on MRI in relapse-onset multiple sclerosis during long-term follow-up. European journal of neurology (2023)
Marcus Werner Koch, Pavle Repovic, Jop Mostert, James D Bowen, Jacynthe Comtois, Eva M M Strijbis, Bernard Uitdehaag, Gary Cutter
Threshold definitions for significant change on the timed 25-foot walk and 9-hole peg test in primary progressive multiple sclerosis. European journal of neurology (2023)
Marcus Werner Koch
Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS). Journal of neurology, neurosurgery, and psychiatry (2023)
Marcus Werner Koch, Ester Moral, Luis Brieva, Jop Mostert, Eva M M Strijbis, Jacynthe Comtois, Pavle Repovic, James D Bowen, Jerry S Wolinsky, Fred D Lublin, Gary R Cutter
Relapse recovery in relapsing-remitting multiple sclerosis: An analysis of the CombiRx dataset. Multiple sclerosis (Houndmills, Basingstoke, England) (2023)
Marcus Werner Koch, Jop Mostert, Pavle Repovic, James D Bowen, Jacynthe Comtois, Eva Strijbis, Bernard Uitdehaag, Gary Cutter
The timed 25-foot walk is a more sensitive outcome measure than the EDSS for PPMS trials: an analysis of the PROMISE clinical trial dataset. Journal of neurology 269 (10) (2022)
Eva Mm Strijbis, Pavle Repovic, Jop Mostert, James D Bowen, Bernard Mj Uitdehaag, Gary Cutter, Marcus Werner Koch
The MSIS-29 and SF-36 as outcomes in secondary progressive MS trials. Multiple sclerosis (Houndmills, Basingstoke, England) 28 (10) (2022)
Carlos Rodrigo Cámara-Lemarroy, Claudia Silva, Jit Gohill, V Wee Yong, Marcus Werner Koch
Serum neurofilament-light and glial fibrillary acidic protein levels in hydroxychloroquine-treated primary progressive multiple sclerosis. European journal of neurology (2022)
Marcus Werner Koch, Jop Mostert, Pavle Repovic, James D Bowen, Jerry S Wolinsky, Fred D Lublin, Eva Strijbis, Gary Cutter
Early first-line treatment response and subsequent disability worsening in relapsing-remitting multiple sclerosis. European journal of neurology 29 (4) (2021)
Marcus Werner Koch, Sharanjit Kaur, Kayla Sage, Janet Kim, Myriam Levesque-Roy, Graziela Cerchiaro, Voon Wee Yong, Gary R Cutter, Luanne M Metz
Hydroxychloroquine for Primary Progressive Multiple Sclerosis. Annals of neurology 90 (6) (2021)
Marcus Werner Koch, Jop P Mostert, Bernard Uitdehaag, Gary Cutter
A comparison of clinical outcomes in PPMS in the INFORMS original trial data set. Multiple sclerosis (Houndmills, Basingstoke, England) 27 (12) (2021)
Marcus Werner Koch, Jop Mostert, Pavle Repovic, James D Bowen, Eva Strijbis, Bernard Uitdehaag, Gary Cutter
Impact of clinical outcomes and imaging measures on health-related quality of life in secondary progressive MS. Multiple sclerosis (Houndmills, Basingstoke, England) 28 (8) (2021)
Marcus Werner Koch, Jop Mostert, Yinan Zhang, Jerry S Wolinsky, Fred D Lublin, Eva Strijbis, Gary Cutter
Association of Age With Contrast-Enhancing Lesions Across the Multiple Sclerosis Disease Spectrum. Neurology 97 (13) (2021)
Marcus Werner Koch, Jop Mostert, Pavle Repovic, James D Bowen, Eva Strijbis, Bernard Uitdehaag, Gary Cutter
Smoking, obesity, and disability worsening in PPMS: an analysis of the INFORMS original trial dataset. Journal of neurology (2021)
Marcus Werner Koch, Luanne M Metz, Gary Cutter
An enrichment strategy for clinical trials in SPMS. Multiple sclerosis (Houndmills, Basingstoke, England) 27 (12) (2021)
Marcus Werner Koch, Jop Mostert, Pavle Repovic, James D Bowen, Eva Strijbis, Bernard Uitdehaag, Gary Cutter
MRI brain volume loss, lesion burden, and clinical outcome in secondary progressive multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England) (2021)
Marcus Werner Koch, Jop Mostert, Pavle Repovic, James D Bowen, Bernard Uitdehaag, Gary Cutter
Is the Symbol Digit Modalities Test a useful outcome in secondary progressive multiple sclerosis? European journal of neurology 28 (6) (2021)
Marcus Werner Koch, Kayla Sage, Sharanjit Kaur, Janet Kim, Graziela Cerchiaro, V Wee Yong, Gary R Cutter, Luanne M Metz
Repurposing Domperidone in Secondary Progressive Multiple Sclerosis: A Simon 2-Stage Phase 2 Futility Trial. Neurology 96 (18) (2021)
Marcus Werner Koch, Jop Mostert, Jamie Greenfield, Wei-Qiao Liu, Luanne Metz
Gadolinium enhancement on cranial MRI in multiple sclerosis is age dependent. Journal of neurology 267 (9) (2020)
Marcus Werner Koch, Jop Mostert, Pavle Repovic, James D Bowen, Bernard Uitdehaag, Gary Cutter
Reliability of Outcome Measures in Clinical Trials in Secondary Progressive Multiple Sclerosis. Neurology 96 (1) (2020)
Marcus Werner Koch, Y Ilnytskyy, A Golubov, L M Metz, V W Yong, O Kovalchuk
Global transcriptome profiling of mild relapsing-remitting versus primary progressive multiple sclerosis. European journal of neurology 25 (4) (2018)

Marcus Werner Koch.css-eqlu8i{font-size:small;padding-left:4px;} (Eva Mm Strijbis, Marcus Koch, Marcus W Koch, Marcus W Koch, M W Koch)

Publication Activity (10 Years)

Top Topics

Top Venues

Marcus Werner Koch (Eva Mm Strijbis, Marcus Koch, Marcus W Koch, Marcus W Koch, M W Koch)